Evercore ISI Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)
Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...
Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Lowered to $26.00 at Barclays
Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...
Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...
FiercePharma4d
Teva, despite delivering in 2024, startles investors with subdued 2025 guidance
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.
Teva Pharmaceutical (TEVA) Gets a Buy from Argus Research
Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...
Teva (yes, like the sandals) makes winter boots now. We tested them in a polar vortex.
Teva’s first pair of true winter boots deliver on their promises. They’re not meant for arctic adventures but are great at ...
Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...